Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

Kalohexis

Private
#Obesity#Cachexia#Metabolic Disease

Private Northbrook, IL biotech developing melanocortin-system-targeted peptides for obesity, cachexia and related metabolic disorders. Spun out of parent in early 2026.

Company Info

Sector:Therapeutic Peptides
Headquarters:Northbrook, IL, USA
Founded:2026
Website:www.kalohexis.com/

Upcoming Milestones & Key Dates

2026-Q3
IPO

Confidential IPO filing (S-1)

2027-H1
regulatory

Expected IND filing for lead obesity program

Clinical Development Pipeline

Undisclosed

Target: Melanocortin-4 receptor
Obesity
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Undisclosed

Target: Melanocortin system
Cachexia
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Undisclosed

Target: Melanocortin system
Additional metabolic indications
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Careers & Job Openings

See all open roles

All departments
See company careers site
Apply Now →